Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling".
Publication/Presentation Date
12-11-2012
Abstract
Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) play important roles in tumor growth, which has stimulated efforts toward the design of targeted cancer therapeutics that inhibit their function. A growing body of literature indicates that EGFR and mTOR are also essential to support a functional innate immune response. Hence, although combination therapies that block both EGFR and mTOR may have improved activity against tumors, they may also place patients at risk of fulminant infections. We discuss data supporting this hypothesis.
Volume
5
Issue
254
First Page
5
Last Page
5
ISSN
1937-9145
Published In/Presented At
Burtness, B., Marur, S., Bauman, J. E., Golemis, E. A., Mehra, R., & Cohen, S. J. (2012). Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling". Science signaling, 5(254), lc5. https://doi.org/10.1126/scisignal.2003734
Disciplines
Medicine and Health Sciences
PubMedID
23233526
Department(s)
Hematology-Medical Oncology Division
Document Type
Article